Skip to main content
NRCNRC HealthSell5.7·$22.40+0.27%
Open full analysis

NRC Health (NRC) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Health Information Services

Sell if holding. Analyst target reached at $22.40 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (1.7% away).

NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and... Read more

$22.40-0.9% A.UpsideScore 5.7/10#8 of 24 Health Information Services
QualityF-score7 / 9FCF yield3.91%
IncomeYield2.68%(5y avg 2.06%)Payout143.59%at-risk
Stop $20.83Target $22.20(resistance)A.R:R -0.8:1
Analyst target$23.00+2.7%1 analysts
Range unavailable (1 analysts)

Sell if holding. Analyst target reached at $22.40 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (1.7% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Jul 27, 202623d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Analyst target reached - limited upside remaining
Near 52-week high (1.7% away)
Leverage penalty (D/E 5.8): -1.5

Key Metrics

P/E (TTM)57.4
P/E (Fwd)20.9
Mkt Cap$505M
EV/EBITDA16.8
Profit Mgn6.5%
ROE41.9%
Rev Growth3.7%
Beta0.38
Dividend2.68%
Rating analysts8

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.57bullish
IV53%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
0.5
Bollinger
0.6
52w Position
9.8

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
Dividend Safety
5.2
Earnings concerns: 2B/2MDividend: 268.0%

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
2.5
Value Rank
4.3
Quality Rank
8.7
Superior ROE vs peers
GatesA.R:R -0.8=NEGATIVEMomentum 6.6>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 23d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
78 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $17.21Resistance $22.65

Price Targets

$21
$22
A.Upside-0.9%
A.R:R-0.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-12.7% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-27 (23d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NRC stock a buy right now?

Sell if holding. Analyst target reached at $22.40 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (1.7% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $20.83. Score 5.7/10, moderate confidence.

What is the NRC stock price target?

Take-profit target: $22.20 (-0.9% upside). Prior stop was $20.83. Stop-loss: $20.83.

What are the risks of investing in NRC?

Analyst target reached - limited upside remaining; Near 52-week high (1.7% away); Leverage penalty (D/E 5.8): -1.5.

Is NRC overvalued or undervalued?

NRC Health trades at a P/E of 57.4 (forward 20.9). TrendMatrix value score: 6.4/10. Verdict: Sell.

What do analysts say about NRC?

8 analysts cover NRC with a consensus score of 2.3/5. Average price target: $23.

What does NRC Health do?NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare...

NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments. It also provides patient experience solutions, a cross-continuum multi-mode digital platform that collects and measures data to improve patient experience, engagement, and loyalty; employee experience solutions, which combines health care with technology comprising engagement, pulse, lifecycle, culture of safety, and magnet RN satisfaction; and consumer experience solution that offers online reputation solutions, community insights, and cross-journey listening through nGage. In addition, the company offers Huey, an AI engine built for Human Understanding that serves as a healthcare experience management companion; and governance solutions provided through national conferences, publications, advisory services, and an online portal for not-for-profit health system boards of directors, executives, and physician leadership. Further, it provides patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. The company was formerly known as National Research Corporation and changed its name to NRC Health April 2026. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.

Related stocks: WAY (Waystar Holding Corp.) · OMDA (Omada Health, Inc.) · WEAV (Weave Communications, Inc.) · PRVA (Privia Health Group, Inc.) · CTEV (Claritev Corporation)
Home Stocks NRC

Latest news

No recent news